Cargando…
Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature constr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371455/ https://www.ncbi.nlm.nih.gov/pubmed/34421308 http://dx.doi.org/10.2147/IJGM.S325240 |
_version_ | 1783739645682515968 |
---|---|
author | Qi, Xiangjun Chen, Guoming Chen, Zhuangzhong Li, Jing Chen, Wenmin Lin, Jietao Lin, Lizhu |
author_facet | Qi, Xiangjun Chen, Guoming Chen, Zhuangzhong Li, Jing Chen, Wenmin Lin, Jietao Lin, Lizhu |
author_sort | Qi, Xiangjun |
collection | PubMed |
description | BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma. METHODS: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. RESULTS: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group. CONCLUSION: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels. |
format | Online Article Text |
id | pubmed-8371455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-83714552021-08-19 Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature Qi, Xiangjun Chen, Guoming Chen, Zhuangzhong Li, Jing Chen, Wenmin Lin, Jietao Lin, Lizhu Int J Gen Med Original Research BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma. METHODS: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. RESULTS: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group. CONCLUSION: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels. Dove 2021-08-11 /pmc/articles/PMC8371455/ /pubmed/34421308 http://dx.doi.org/10.2147/IJGM.S325240 Text en © 2021 Qi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Qi, Xiangjun Chen, Guoming Chen, Zhuangzhong Li, Jing Chen, Wenmin Lin, Jietao Lin, Lizhu Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature |
title | Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature |
title_full | Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature |
title_fullStr | Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature |
title_full_unstemmed | Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature |
title_short | Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature |
title_sort | construction of a novel lung adenocarcinoma immune-related lncrna pair signature |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371455/ https://www.ncbi.nlm.nih.gov/pubmed/34421308 http://dx.doi.org/10.2147/IJGM.S325240 |
work_keys_str_mv | AT qixiangjun constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature AT chenguoming constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature AT chenzhuangzhong constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature AT lijing constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature AT chenwenmin constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature AT linjietao constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature AT linlizhu constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature |